Blockade of soluble epoxide hydrolase attenuates post-ischemic neuronal hyperexcitation and confers resilience against stroke with TrkB activation

Li-Hsin Chang, Hui-Ching Lin, Shiang-Suo Huang, I-Chih Chen, Kai-Wen Chu, Chun-Lien Chih, Yao-Wen Liang, Yi-Chung Lee, Yi-Hsuan Lee & I-Hui Lee

Inhibition and deletion of soluble epoxide hydrolase (sEH) has been suggested to ameliorate infarction in experimental ischemic stroke possibly via vasoactive epoxyeicosatrienoic acids. However, it is unknown whether the neuroprotective mechanisms involve alteration of post-ischemic neuronal transmission and neurotrophic signaling. We used a permanent middle cerebral artery occlusion (MCAO) model in adult wild-type mice with the sEH inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA) post-treatment and in sEH knockout (sEH KO) mice. We found that sensorimotor recovery was significantly enhanced after MCAO in both AUDA-treated and sEH KO mice, with decreased sEH activity and brain infarction. Decreased post-ischemic long-term potentiation (iLTP) was observed in an ex vivo hippocampal oxygen-glucose deprivation model. Tropomyosin receptor kinase B (TrkB) activation, rather than glutamate receptor alteration, was consistently found after the different manipulations. Immunohistochemistry further revealed peri-infarct neuronal TrkB activation and microvasculature augmentation in AUDA-treated and sEH KO mice, suggesting parallel neurovascular enhancement. Mechanistically, pretreatment with a selective TrkB antagonist ANA12 countered the effect of iLTP attenuation induced by sEH deletion ex vivo and abolished the infarct reduction in vivo. Together, the neuroprotective effects of sEH inhibition and gene deletion can both be mediated partially via enhancement of TrkB signaling which attenuated post-ischemic neuroexcitation and neurological deficits.

Soluble epoxide hydrolase (sEH), which is encoded by the EPHX2 gene, is found in nearly all mammalian tissues as an enzyme with dual activities, including the C-terminal hydrolase activity responsible for the metabolism of epoxyeicosatrienoic acids (EETs) into less-active dihydroxyeicosatrienoic acids (DHETs), and the N-terminal phosphatase activity. EETs and related epoxide fatty acids are signaling fatty acids generated from arachidonic acid through the cytochrome P450 epoxygenase pathway and have been shown to have protective effects on vasodilation, angiogenesis, as well as anti-inflammation. It has been shown that sEH expression in the mammalian brain occurs mainly in astrocytes and vascular endothelial and smooth muscle cells as well as in a few neuronal populations in the striatum, cortex, and hippocampus. Following middle cerebral artery occlusion (MCAO) in adult rodents, cytochrome P450 enzymes and arachidonic acid metabolites have been suggested to play essential roles in regulating cerebral blood flow and inflammatory responses to ischemia. Systemic administration of 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), an sEH inhibitor, has been shown to...
reduce infarct size and ameliorate functional deficits; these effects were attributed, at least partially, to increased EET levels and enhanced cerebral blood flow. Similarly, sEH knockout (sEH KO) mice were also protected from ischemic stroke. Compared to wild-type (WT) controls, sEH KO mice had smaller infarcts in association with increased EET levels and collateral blood flow. In contrast, transgenic mice with endothelial-specific overexpression of human sEH exhibited impaired vasodilatation and enlarged infarcts after MCAO in female but not in male mice, suggesting that sEH may serve as a vasoactive modulator and a potential therapeutically targetable biomarker in ischemic stroke. However, the functional relevance of neurogliial sEH expression, as well as sEH blockade-mediated neuroprotective mechanisms against stroke, remain elusive.

A recent study reported that sEH KO mice subjected to MCAO had decreased infarcts in association with elevated brain-derived neurotrophic factor (BDNF) expression predominantly in peri-infarct glial fibrillary acidic protein (GFAP)-positive astrocytes. The infarct reduction was countered by intracerebroventricular injection of a potent but non-selective tyrosine receptor kinase inhibitor, K252a, which acts on tropomyosin receptor kinase (TrkA), TrkB or TrkC. Moreover, exogenous 14,15-EET treatment in cultured murine astrocytes and a human astrogloma cell line subjected to oxygen-glucose deprivation (OGD) increased BDNF expression and cell viability, indicating that 14,15-EET-mediated production of BDNF by astrocytes and this effect might protect against ischemic injury in sEH KO mice. In another study that used lipopolysaccharide-induced inflammation and repeated social defeat stress models, pretreatment with an sEH inhibitor and sEH KO were found to prevent the onset of depression-like behaviors and to increase BDNF-TrkB expression in the prefrontal cortex and the hippocampus, suggesting that BDNF-TrkB signaling confers the stress resilience in association with sEH blockade.

Nevertheless, these interesting findings have not elucidated how sEH blockade alters neural excitability after ischemic injury and whether BDNF-TrkB signaling mediates such neuroprotective effects. BDNF is a paracrine neurotrophic factor that is secreted by almost all cell types in the brain. BDNF binds to the high-affinity transmembrane receptor TrkB and the low-affinity p75 neurotrophin receptor to mediate various neuroplastic and neuroprotective effects throughout life. Here, we investigate how pharmacological inhibition and gene deletion of sEH exerts neuroexcitatory modulation and neuroprotection against ischemic hypoxic brain injury by utilizing N-[2-[[[(Hexahydro-2-oxo-1H-azepin-3-yl) amino]-carbonyl]phenyl]-benzo[b]thiophene-2-carboxamide (ANA12), a selective TrkB inhibitor, and focusing on the role of BDNF-TrkB signaling and glutamate receptors.

To do so, we adopted a permanent mouse MCAO model in vivo and post-ischemic long-term potentiation (iLTP) measurements in ex vivo hippocampal slices subjected to OGD. Given the potential neurovascular benefits of sEH inhibitors in preclinical stroke models and their safety profiles in humans, our findings indicate that TrkB activation is involved in sEH blockade-mediated neuroprotection in acute ischemic stroke and open new possibilities for combination treatments with neuroprotectants and reperfusion by thrombolytic and/or endovascular thrombectomy treatments.

Results

Both pharmacological inhibition and gene deletion of sEH attenuate acute cerebral infarction, ischemia-induced sEH activity, and sensorimotor deficits. Consistent with previous studies, we found that both the AUDA-treated mice and soluble epoxide hydrolase knockout (sEH KO) mice exhibited a significant reduction of infarct volume relative to the vehicle-treated and wild type (WT) mice (Fig. 1A,B). Acute cerebral ischemia increased sEH activity in WT mice. AUDA treatment decreased sEH activity relative to vehicle treatment, while no sEH activity was detected in the brains of sEH KO mice either before or after middle cerebral artery occlusion (MCAO) (Fig. 1C). Cytochrome P450 (CYP) epoxygenases and hydroxylases metabolize arachidonic acid into epoxyeicosatrienoic acids (EETs) (CYP2B, CYP2C, and CYP2J isoforms) and hydroxyicosatetraenoic acids (HETEs) (CYP4A and CYP4F isoforms), respectively. EETs are degraded by sEH into the corresponding less-active dihydroxyeicosatrienoic acids (DHETs). Thus, we measured 14,15-DHET levels as surrogates for EET-to-DHET ratios and found that sEH inhibition decreased 14,15-DHET levels relative to those found in controls; however, sEH KO had no impact (Fig. 1D). By contrast, sEH KO significantly increased the 20-HETE levels relative to those in controls (Fig. 1D), which is in line with others’ findings. These findings suggest that reduced EET degradation in sEH KO mice might have shifted the cytochrome P450 monooxygenase metabolism from epoxy-arachidonic acid derivatives to more hydroxyl-arachidonic acid derivatives. Moreover, the AUDA-treated mice had enhanced sensorimotor coordination and increased latencies on the accelerating rotorod test (Fig. 1E). They also displayed significantly improved performance on the skilled forelimb reaching task (Fig. 1F) and the adhesive removal test at 7 days post-MCAO compared to the vehicle-treated mice (Fig. 1G). Likewise, compared to the WT controls, the sEH KO mice had significantly increased latencies in the rotorod test (Fig. 1H) and the time taken to initiate contact and completely remove the adhesive was shorter at 1 and 2 days after MCAO (Fig. 1I). Additionally, to elucidate possible vascular mechanisms involved in the sEH-blockade neuroprotection, we longitudinally measured the tail blood pressure as well as peri-infarct cortical blood flow before and after MCAO in a separate experiment (see Supplementary methods). We found that the AUDA-treated group had a significant decrease in mean blood pressure at 24 hours after MCAO compared with the vehicle-treated and sEH KO groups (Supplementary Fig. 1A). However, the simultaneous changes of peri-infarct cortical blood flow rate in ratio to the baseline before MCAO did not show significant difference among the groups by 24 hours after MCAO (Supplementary Fig. 1B). The student t-test used in the comparisons of infarct size, sEH activity, and lipid metabolites. The repeated measures ANOVA was used to determine the behavioral changes, followed by a post-hoc with Bonferroni correction if there was a significant difference.

Both inhibition and deletion of sEH attenuate post-ischemic hyperexcitation of Schaffer collateral-CA1 synapses in the hippocampus. Oxygen glucose deprivation (OGD)-induced post-ischemic long-term potentiation (iLTP) has been attributed to abnormal Ca²⁺ influx via the overactivation of glutamate receptors, predominantly the N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-
Figure 1. Pharmacological inhibition and gene deletion of soluble epoxide hydrolase (sEH) attenuate acute cerebral infarction, sEH activity, and sensorimotor deficits. (A) Representative brain slices from vehicle- vs. sEH inhibitor (AUDa)-treated C57BL/6 mice that were stained with vital dye, and from wild-type (WT) vs. sEH knockout (sEH KO) mice at 48 hours after middle cerebral artery occlusion (MCAO) (the white crosses indicate the peri-infarct cortices on which the immunohistochemistry was shown in Fig. 4). (B) The infarct volume was reduced in the AUDa-treated group (n = 18) compared to the vehicle-treated group (n = 17). Similarly, the sEH KO group (n = 8) had significantly smaller infarcts than the WT group (n = 8). (C) The average sEH hydrolase activity in the ipsilesional hemisphere (represented as fold changes relative to the normal WT baseline) increased after MCAO in the control vehicle and WT groups (n = 5/group). AUDa treatment reduced sEH activity, and there was no sEH activity in the sEH KO mice relative to the corresponding controls (n = 5/group). (D) The mean level of 14,15-DHET in the ipsilesional hemisphere decreased with AUDa treatment relative to that observed following vehicle treatment but did not differ between the WT and sEH KO groups. However, the mean level of 20-HETE was elevated in the sEH KO group compared to the WT group (n = 5/group). (E) The performance of the AUDa-treated mice (n = 9) was better than that of the vehicle-treated controls (n = 10) on the rotarod test, (F) the pasta matrix reaching task and (G) the adhesive removal test by 7 days after MCAO. (H) Likewise, the sEH KO mice (n = 5) exhibited reduced sensorimotor deficits compared to the WT mice (n = 6) during the rotarod test, (I) reduced adhesive contact and (J) reduced adhesive removal time by 48 hours after MCAO. The results are expressed as the mean ± standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001 compared with controls.
-4-isoxazolepropionic acid (AMPA) receptor types. During the 5 minutes of OGD induction, there were no obvious differences in field excitatory postsynaptic potential (fEPSP) amplitudes among the acute hippocampal slices from WT, WT/Vehicle, sEH KO and AUDA-treated (n = 6/group) mice (Fig. 2A,B), indicating the loss of synaptic potentials was similar in all groups. Interestingly, following reperfusion with oxygenated glucose solution and during the last 10 minutes of iLTP expression, the fEPSP amplitude was significantly reduced in the AUDA-treated and sEH KO slices (Fig. 2C), suggesting that sEH blockade and deletion reduced post-ischemic neuronal hyperexcitation. The student’s t-test was used to determine any statistical difference.

Both sEH inhibition and deletion consistently upregulate post-stroke TrkB activation. To investigate how sEH is involved in postsynaptic excitability, we first examined expression of NMDA and AMPA glutamate receptors, including the NMDAR subunits GluN2A, GluN2B and the Ca2+-impermeable AMPAR subunit GluA2. AUDA treatment upregulated the level of the NMDAR GluN2A subunit but did not have a significant effect on GluN2B or GluA2 subunit after MCAO (Supplementary Fig. 2A). On the other hand, in sEH KO mice, GluN2B level, but not GluN2A, was significantly upregulated at normal baseline and after MCAO compared to that in the WT mice. In sEH KO mice, GluA2 level was increased at normal baseline compared that in WT controls. After MCAO, GluA2 level did not change in the sEH KO group but significantly increased in the WT controls (Supplementary Fig. 2B). Increased GluN2A subunits might trigger pro-survival signaling and contribute to neuroprotection, as well as prevent Ca2+ influx and thus decrease iLTP and excitotoxicity. In contrast, GluN2B subunits have been suggested to be detrimental and critical for iLTP induction, while GluN2A and GluN2B were inconsistently regulated by sEH pharmacological inhibition and gene deletion, which needs further investigation, other mechanisms might be involved in the sEH blockade-mediated neuroprotection.

To investigate how sEH is involved in postsynaptic excitability, we then investigated BDNF-TrkB and p75 neurotrophin receptor (p75NTR) signaling, which induces NMDAR trafficking and activation. Compared to vehicle treatment, AUDA treatment upregulated mature BDNF (17 kDa) and phosphorylated TrkB (p-TrkB) (90 kDa, phosphorylated Y515). Pro-BDNF (35 kDa) and p75NTR (70 kDa) levels did not differ between groups (Fig. 3A). On the other hand, the sEH KO mice exhibited overexpression of pro-BDNF and p-TrkB, but not BDNF, at baseline and persistently upregulated p-TrkB after MCAO compared to the WT group. In the sEH KO mice, p75NTR...
expression was downregulated at the normal state and after MCAO (Fig. 3B). Enhancement of TrkB phosphorylation and downregulation of p75NTR suggests that these effects might be mediated more by BDNF-TrkB than by pro-BDNF-p75NTR signaling, which may enhance neuronal survival instead of apoptosis. Taken together,
sEH inhibition and deletion consistently increased the activation of the neurotrophin TrkB, which may mediate the amelioration of infarcts and neurological deficits. The student's t-test was used to determine the significance of the differences in protein levels.

**Pharmacological inhibition and sEH gene deletion increase neuronal TrkB and microvasculature in the peri-infarct cortex.** Pharmacological inhibition of sEH significantly increased CD31-positive endothelial cells in the peri-infarct region, while increased CD31-positive cells were observed before and after MCAO in sEH KO mice (Fig. 4A–F, S). Additionally, more NeuN-positive neuronal populations that were double-labeled for p-TrkB immunoreactivity that partially co-localized with NeuN-positive neurons, particularly in the sEH KO and AUDA-treated mice (arrows) (T). The percentage of NeuN- and p-TrkB-positive double labeling in the neuronal population was significantly increased compared to that in the corresponding controls. (M–R, U–V) GFAP-positive astrogliosis and Iba1-positive microglial infiltration decreased in post-MCAO sEH KO and AUDA treatment groups relative to that in the corresponding controls. The scale bar represents 50 μm.

\*p < 0.05, \**p < 0.01, \***p < 0.001.
suggest that increased p-TrkB in neurons, as well as enhanced collateral microvasculature and reduced inflammatory gliosis, may be associated with the neuroprotection mechanisms by sEH blockade. The student’s t-test was used to determine the significance of differences in quantitative immunoreactivities.

**sEH blockade-mediated neuroprotection requires TrkB overactivation.** To determine whether TrkB mediates the neuroprotection conferred by sEH blockade and deletion, ANA12, a selective TrkB receptor inhibitor, was used for pretreatment in the OGD and MCAO models. During OGD induction, the fEPSP amplitude did not differ among the WT/vehicle, WT/ANA12, sEH KO/vehicle and sEH KO/ANA12 groups (Fig. 5A). During iLTP expression, we found that the iLTP amplitude of the WT/vehicle and WT/ANA12 groups increased similarly, suggesting that ANA12 did not affect injury (Fig. 5A,B). Importantly, the iLTP amplitude of the sEH KO/ANA12 group was significantly higher than that of the sEH KO/vehicle group and similar to that of the WT/vehicle group, suggesting that sEH KO reduced iLTP through TrkB signaling (Fig. 5A,B). Similarly, we found that WT/ANA12 pretreatment did not affect the brain infarct compared to that observed in the WT/vehicle controls; however, sEH KO/ANA12 reversed the protective effects of sEH KO/vehicle in vivo 48 hours after MCAO (Fig. 5C,D). Together, the findings suggest a novel framework for how sEH increases after ischemia potentiate...
injury through negative regulation of TrkB and EET levels (Fig. 5E). Hence, AUDA inhibition and sEH gene deletion not only increased EET levels to enhance cerebrovascular collaterals but epoxy fatty acids might possibly activate TrkB to protect neurons and reduce ILTP hyperexcitability, leading to decreased infarcts and functional deficits. The student’s t-test was used to determine the statistical significance of differences in fEPSP amplitude and infarct volume.

Discussion

Both pharmacological inhibition (AUDA) and genetic deletion of sEH significantly ameliorated ischemic infarction and sensorimotor deficits in association with overexpression of brain p-TrkB and NMDA-type glutamate receptors in adult mice. Moreover, neuronal expression of p-TrkB, as well as collateral microvasculature, were significantly enhanced in the peri-infarct cortex, while astrogliosis and microglial activation were reduced. We demonstrated, for the first time, that both the inhibition and deletion of sEH reduced post-ischemic neuronal hyperexcitability, i.e., ILTP, in an ex vivo OGD model of adult hippocampal slices. Importantly, pretreatment with a selective TrkB inhibitor before OGD and before MCAO reversed the ILTP and infarct attenuation conferred by sEH deletion, suggesting that TrkB activation was involved in the neuroprotective effects. Together, these findings indicate that sEH potentiates ischemic injuries and neuronal hyperexcitability not only through the degradation of protective EETs but also through negative regulation of the TrkB activation.

The impact of sEH on synaptic plasticity is largely unknown. We previously reported that sEH inhibition (AUDA) enhanced neuronal synaptic transmission and physiological long-term potentiation (LTP) following high-frequency stimulation using whole-cell and extracellular recordings in the mouse prefrontal cortex ex vivo. These enhancements were associated with the overexpression of postsynaptic NMDAR and AMPAR subunits as well as extracellular signal-regulated kinase (ERK) phosphorylation. The activation of ERK signaling mediates neuronal responses to neurotrophic factors and is required for NMDA-dependent LTP. By contrast, here we demonstrate that both sEH inhibition and gene deletion decreased ILTP following OGD insult using extracellular recordings in the hippocampus. These decreases were associated with the overexpression of p-TrkB; however, the upregulation of NMDAR and AMPAR subunits was inconsistent across the models. The addition of the selective TrkB inhibitor ANA12 reversed the attenuation of ILTP ex vivo and the infarct size reduction in vivo. Hence, the neuroprotective effect of sEH inhibition may be mediated by TrkB activation rather than through glutamate receptors. It has been well documented that BDNF-TrkB activation enhances synaptic transmission and plasticity. Recently, it has been suggested that sEH deletion and EETs promoted astrocyte-derived BDNF production and exerted neuroprotective effects during OGD injury through BDNF-TrkB-ERK activation in vitro. Moreover, pharmacological inhibition and genetic deletion of sEH have been shown to prevent the onset of depression-like behaviors induced by repeated experimental social defeat stress in association with upregulated BDNF-TrkB expression in the prefrontal cortex and hippocampus. Our findings suggest that sEH blockade may not only enhance physiological LTP but also attenuate OGD-induced ILTP. The attenuation of ILTP and infarction against ischemic injury by pharmacological inhibition and genetic deletion of sEH involves, at least in part, TrkB activation. The neural mechanisms can be further elucidated using forebrain-specific, glia-specific or neuron-specific TrkB knockout mice.

There are limitations to our study, and further studies are needed. First, we did not have direct 14,15-EET measurement data because a liquid chromatograph-mass spectrometer was not available, and the manufacturer of the ELISA kit stopped production before we could finish our experiments. According to previous publications, sEH blockade likely increases EET levels in the brain. It is unknown whether the neuroprotective effects of ILTP attenuation and p-TrkB overexpression might be EET-dependent. Second, we could not determine which glutamate receptor might mediate ILTP modulation via sEH blockade using extracellular fEPSPs. Whole-cell patch clamp recordings or synaptoneurosome isolation would be required to make this distinction. The mechanisms underlying the effects of sEH on synaptic plasticity remain unclear. Third, we can not exclude possible vascular mechanisms by sEH blockade because AUDA treatment, but not sEH KO, lowered blood pressure after MCAO. Nevertheless, we did not observe significant changes in peri-infarct blood flow by sEH blockade. Fourth, we used an ex vivo hippocampal OGD model for convenience of ILTP recording, which is not supplied by MCA, therefore not accurately reflective of an in vivo MCAO model. Fifth, BDNF mRNA and protein are present at extremely low levels in the brain, and after ischemic injury, brain BDNF expression increases in a transient manner and then dramatically decreases. Consistent with TrkB overexpression already before MCAO, sEH gene deletion did not significantly increase BDNF protein levels after MCAO in the current study. Additionally, we could not completely rule out that neurotrophin-4-TrkB signaling also plays a role in TrkB activation. Finally, the pharmacokinetics of ANA12 in vivo limit its effects to 4 hours; more frequent administration of ANA12 may be feasible for TrkB inhibition.

In conclusion, we demonstrated the protective potential of sEH inhibition after acute ischemic stroke in amelioration of functional deficits and provided evidence that this protection involves TrkB activation. Pharmacological inhibition and gene deletion of sEH attenuated ILTP following OGD insult in the hippocampus ex vivo, and this effect was reversed by selective TrkB inhibition. sEH genetic polymorphisms may increase or decrease sEH activity, which might affect TrkB activity. Our findings provide novel insights into the TrkB-mediated neuroprotection and ischemic resilience conferred by pharmacological inhibition and gene deletion of sEH.

Materials and Methods

The datasets generated or analyzed during the current study are available from the corresponding author on reasonable request.
Permanent MCAO model and study design. Adult male C57BL/6J WT mice (10–12 weeks old, 22–26 g body weight, BioLASCO Taiwan Co., Ltd, n = 123) and sEH KO mice (B6.129X-Ephx2<sup>−/−</sup>/J, The Jackson Laboratory, n = 53) were anesthetized with intraperitoneally administered chloral hydrate (450 mg/kg body weight in saline) and received permanent middle cerebral artery occlusion (MCAO) surgery using a procedure described previously<sup>47</sup>. Briefly, the dominant limb was determined based on the skilled forelimb reaching test (see below). Subsequently, the distal MCA contralateral to the dominant limb was exposed by craniotomy and directly cauterized, followed by simultaneous occlusion of the bilateral common carotid arteries using microclips for 20 minutes to paralyze the dominant forelimb. The body temperature was maintained with a homeothermic heating pad with rectal temperature control at 37 ± 0.5 °C. For the pharmacological inhibition of sEH, 61 WT mice were randomly allocated to receive a daily intraperitoneal injection of either vehicle (2% dimethyl sulfoxide (DMSO), Sigma-Aldrich, n = 40) or AUDA<sup>48</sup> (10 mg/kg in 2% DMSO, Cayman Chemical, n = 41) for 7 consecutive days post-MCAO. The animal experiments were approved by the Institutional Animal Care and Use Committee at the Taipei Veterans General Hospital. All methods were performed in accordance with the relevant guidelines and regulations.

Behavioral tests. Before MCAO and 1 to 7 days after, blind observers longitudinally measured performance on the rotarod test<sup>49,50</sup>, the skilled forelimb reaching task (pasta matrix reaching task)<sup>51</sup> and the adhesive removal test<sup>52</sup> (AUDA n = 9 vs. vehicle n = 10; sEH KO n = 5 vs. WT n = 6). For the rotarod test, the mice were pre-trained for 5 days before surgery. Within each session, the rotarod speed was increased from 4 to 40 rpm with an acceleration rate of 8 rpm/min. The mice performed 3 times of 10-minute test sessions of running. The latency to fall from the rotarod was recorded and averaged. For the skilled forelimb reaching task, i.e., the pasta matrix reaching task, the mice were pre-trained for 2 weeks to learn to break and retrieve pieces of uncooked capellini from a row of vertically oriented pieces of pasta (matrix) until they achieved a maximum of 30 pieces in 30 minutes. The mouse was placed in an acrylic chamber (15 × 8.5 × 20 cm) containing a slit (13 × 0.5 cm at the center of the 15 cm long side). The capellini matrix was then placed in front of the slit. The number of pieces of pasta removed in 30 minutes were recorded for analysis. For the adhesive removal test, a forelimb was cleaned, and a piece of adhesive tape (0.3 × 0.4 cm) was attached to the limb. The timer started once the mice were placed into a cylinder. The time at which the mouse began to remove the tape and the time at which the tape was completely removed was recorded.

Quantification of infarcts, sEH activity, fatty acids and western blotting. After 2 or 7 days of MCAO and behavioral measurements, the mice were decapitated after intraperitoneal injection of urethane (1–1.5 g/kg). Immediately after, fresh brains were harvested for quantification of infarct size, sEH activity, fatty acids, and proteins. To quantify the infarct, we sectioned the brain into standard 1 mm coronal slices using a brain matrix slicer (Jacobowitz Systems, Zivic-Miller Laboratories Inc.). Stained the brain slices with a 2% solution of the vital dye 2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich) at 37 °C for 30 minutes in the dark and fixed them with 10% formalin at room temperature overnight (AUDA n = 18 vs. vehicle n = 17; sEH KO n = 8 vs. WT n = 8). The area of the infarct was delineated and measured using Ais software (Imaging Research Inc.), and the total volume (in mm<sup>3</sup>) was calculated as the sum of the infarct areas on each slice<sup>53</sup>. Both the surgeon and analyst were blind to the experimental groups.

To measure sEH activity and fatty acids, the ipsilesional hemisphere was isolated, weighed and homogenized with additional T-PER Tissue Protein Extraction (5 µg/mg tissue, ThermoFisher) (n = 5/group). The hydrolase activity of sEH was determined using a cell-based assay kit (Cayman Chemical)<sup>234</sup>, while levels of 14,15-DHET and 20- HETE were determined using enzyme-linked immunosorbent assay (ELISA) kits immediately after the tissue was homogenized according to the manufacturer's instructions (Detoit R&D). For DHET ELISA, the homogenate was acidified with acetic acid, extracted with an equal amount of ethyl acetate several times and then dried using a vacuum concentrator (ThermoFisher). The residue was dissolved in ethanol and diluted with dilution buffer for the ELISA.

For western blotting, the aforementioned fresh homogenate that was prepared in T-PER Tissue Protein Extraction buffer (ThermoFisher) was mixed with 0.5% protease inhibitor (Sigma-Aldrich) and 0.5% phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich) and centrifuged at 10000xg for 20 minutes to obtain supernatants (n = 8/group). The protein concentration of the supernatants was determined using a NanoVue Plus Spectrophotometer. Equal amounts of protein (40 µg) were loaded onto 7.5%, 12% or 15% gels depending on the target protein size. The proteins were then separated using SDS-PAGE, transferred onto polyvinylidene difluoride membranes and blocked with 5% skim milk powder (Fluka) for 60 minutes. The following primary antibodies were then used for incubation overnight at 4 °C: rabbit anti-BDNF (1:500, Origin, TA328613), rabbit anti-phosphorylated TrkB (p-TrkB, 1:500, Abcam, ab109684), rabbit anti-GluN2A (1:1000, Millipore, 05–901 R), rabbit anti-GluN2B (1:1000, Cell Signaling, 4207 S), rabbit anti-p75NTR (1:1000, Abcam, ab52987), rabbit anti-GluA2 (1:1000, Origin, TA326000) and rabbit anti-β-Actin (1:2000, ThermoFisher, PA1–183). The membranes were then incubated with secondary HRP-conjugated antibodies (1:5000, Millipore, AP132P) for 1 hour at room temperature. The immunoreactivity was detected with Clarity Western ECL Substrate (Bio-Rad). X-ray films (Fuji) were exposed for the different duration to ensure optimal densities. Relative optical densities were normalized to the levels of the internal control β-actin and then measured as fold changes using ImageJ<sup>55</sup>.

Immunohistochemistry. After 2 or 7 days of MCAO, the mouse was anesthetized and transcardially perfused with 20 ml normal saline containing 10 U/ml heparin followed by 20 ml 4% paraformaldehyde in phosphate-buffered saline (PBS) (AUDA vs. vehicle n = 5/group; sEH KO vs. WT n = 6/group). The brain was dissected and post-fixed in 4% paraformaldehyde overnight and then transferred to 30% sucrose for days. Afterward, 20µm thickness frozen cryostat brain sections were attached to silane-coated glass slides. The slides were incubated in a blocking solution containing 3% donkey serum albumin (Abcam) and 0.3% Triton X-100.
Electrophysiological recording of hippocampal slices, oxygen-glucose deprivation, and iLTP induction. Adult WT (n = 12) and sEH KO (n = 18) mice were decapitated, and their brains were immediately dissected and placed in ice-cold (4 °C) oxygen-saturated (95% O₂ and 5% CO₂) artificial cerebrospinal fluid (ACSF, pH = 7.4). The brain slices (400 µm thickness) were prepared as described previously and placed in a beaker of oxygenated ACSF at room temperature for at least 1 hour before recording. A single slice was transferred to a recording chamber consisting of a circular well (2 ml volume) and perfused constantly at a rate of 2–3 ml/min at 32 ± 1 °C. A bipolar stimulating electrode (FHC, Bowdoin) was inserted into the Schaffer collaterals to deliver electrical stimuli (duration 150 µs, frequency 0.1 Hz). Field excitatory postsynaptic potentials (fEPSPs) were recorded from the stratum radiatum of the CA1 subregion with a glass pipette containing 1 M NaCl and a Multiclamp 700B amplifier. Baseline field potentials were recorded every 10 s for 10 minutes and adjusted to 30–40% of the maximal responses. For OGD and iLTP induction, glucose-containing ACSF gassed with 95% O₂/5% CO₂ was replaced with sucrose-containing ACSF gassed with 95% N₂/5% CO₂ for 5 minutes. Then, the perfusion solution was switched back to normal ACSF, and the slices were re-oxygenated with 95% O₂/5% CO₂. iLTP was continuously recorded for 60 minutes after OGD. The average fEPSP amplitude during the 5 minutes of OGD induction and the last 10 minutes of iLTP expression were compared across groups (n = 6 slices/group).

Selective TrkB blockade in vivo and ex vivo. To investigate whether TrkB mediated the effects of sEH inhibition and deletion on the attenuation of brain infarction and iLTP, we pre-treated the experimental groups with the selective TrkB inhibitor ANA12, before MCAO and OGD, respectively. WT and sEH KO mice were pretreated with intraperitoneal injection of ANA12 (0.5 mg/kg, MedKoo; n = 5/group) or vehicle (1% DMSO, Sigma-Aldrich; n = 3/group) every 12 hours for 3 times before the MCAO surgery to ensure TrkB inhibition. For the ex vivo experiments, the hippocampal slices from WT and sEH KO mice were pretreated with 10 µM ANA12 or vehicle for 30 minutes before OGD (n = 6 slices/group).

Statistical Analysis. We used SPSS (Windows version 22) for the data analyses. The repeated-measures analysis of variance test (ANOVA) was used to compare the behavioral data, with “time point” as the within-subject factor and “group” as the between-subjects factor. The ANOVA was followed by post-hoc Bonferroni tests at every time point to determine any group difference. We used independent Student’s t-tests or one-way ANOVA to evaluate group differences in infarct size, sEH activity, lipid metabolites, western blotting, immunohistochemistry and fEPSP amplitude measurements. A p-value < 0.05 was considered statistically significant.

References
1. Gill, S. S. & Hammock, B. D. Distribution and properties of a mammalian soluble epoxide hydrolase. *Biochemical pharmacology* 29, 389–395 (1980).
2. Yu, Z. et al. Soluble Epoxyeicosatrienoic Acids. *Circulation Research* 87, 992–998 (2000).
3. Hou, H. H. et al. N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. *Cardiovasc Res* 93, 120–129 (2011).
4. Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C. & Hammock, B. D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertensive. *Hypertension* 39, 690–694 (2002).
5. Alkayed, N. J. et al. Inhibition of brain P-450 arachidonic acid epoxynase decreases baseline cerebral blood flow. *Am J Physiol* 271, H1541–1546 (1996).
6. Michaelis, U. R. & Fleming, I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (ETEs) and cell signaling. *Pharmacology & Therapeutics* 111, 584–595 (2006).
7. Thomson, S. J., Askari, A. & Bishop-Bailey, D. Anti-inflammatory effects of epoxyeicosatrienoic acids. *International journal of vascular medicine* 2012, 605101 (2012).
8. Nodé, K. et al. Anti-inflammatory properties of cytochrome P450 epoxyenase-derived eicosanoids. *Science* 285, 1276–1279 (1999).
9. Schmehel, K. R. et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. *Proceedings of the National Academy of Sciences of the United States of America* 102, 9772–9777 (2005).
10. Norwood, S., Liao, J., Hammock, B. D. & Yang, G.-Y. Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. *American journal of Translational Research* 2, 447–457 (2010).
11. Zhang, W. et al. Soluble epoxide hydrolase: a novel therapeutic target in stroke. *J cereb blood flow metab* 27, 1931–1940 (2007).
12. Bianco, R. A., Agassandian, K., Cassell, M. D., Spector, A. A. & Sigmund, C. D. Characterization of transgenic mice with neuron-specific expression of soluble epoxide hydrolase. *Brain Res* 1291, 60–72 (2009).
13. Marowsky, A., Burgener, J., Falck, J. R., Fritschi, J. M. & Arand, M. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. *Neuroscience* 163, 646–661 (2009).
14. Hori, A. G. et al. 18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase (sEH). *J Nucl Med* (2016).
15. Dorrance, A. M. et al. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl)iodocanonic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. *Journal of cardiovascular pharmacology* 46, 842–848 (2005).
16. Simpkins, A. N. et al. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. *The American journal of pathology* 174, 2086–2095 (2009).
17. Zhang, W. et al. Role of Endothelial Soluble Epoxide Hydrolyase in Cerebrovascular Function and Ischemic Injury. PLoS ONE 8, e61244 (2013).
18. Yuan, L. et al. 14,15-epoxyeicosatrienoic acid promotes production of BDNF from astrocytes and exerts neuroprotective effects during ischemic injury. Neuropathol Appl Neurobiol. (2015).
19. Ren, Q. et al. Gene deficiency and pharmacological inhibition of soluble epoxide hydrolyase confers resilience to repeated social defeat stress. Proceedings of the National Academy of Sciences of the United States of America 113, E1944–E1952 (2016).
20. Barde, Y. A., Edgar, D. & Thoenen, H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1, 549–553 (1982).
21. Levine, E. S., Crozier, R. A., Black, J. B. & Blummer, M. R. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. Proc Natl Acad Sci USA 95, 10235–10239 (1998).
22. Park, H. & Poo, M. M. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 14, 7–23 (2013).
23. Cazorla, M. et al. Identification of a low–molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. The Journal of Clinical Investigation 121, 1846–1857 (2011).
24. Chen, D. et al. Pharmacogenetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolyase, in single- and multiple-dose studies in healthy human subjects. Journal of clinical pharmacology 52, 319–328 (2012).
25. Lazaar, A. L. et al. Pharmacogenomics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolyase inhibitor. British journal of clinical pharmacology 81, 971–979 (2016).
26. Zhang, W. et al. Soluble Epoxide Hydrolyase Gene Deletion Is Protective Against Experimental Cerebral Ischemia. Stroke 39, 2073–2078 (2008).
27. Li, L. et al. Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolyase on cardiac fibrosis. PLoS ONE 9, e94092 (2014).
28. Zhu, Y. et al. Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolyase-Deficient Mice. PLoS One 11, e0145645 (2016).
29. Crepel, V., Hammond, C., Chanez, P., Diabira, D. & Ben-Ari, Y. A selective LTP of NMDA receptor-mediated currents induced by anoxia in CA1 hippocampal neurons. Journal of neuropathology and physiology 70, 2045 (1993).
30. Piccon, B. et al. NR2B Subunit Exerts a Critical Role in Postsynaptic Somatic Plasticity, Stroke 37, 1895 (2006).
31. Liu, Y. et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27, 2846–2857 (2007).
32. Isaac, J. T. R., Ashby, M. C. & McBain, C. J. The Role of the GluR2 Subunit in AMPA Receptor Function and Somatic Plasticity. Neuron 54, 859-871.
33. Piccon, B. et al. NR2B subunit exerts a critical role in postsynaptic somatic plasticity. Stroke 37, 1895–1901 (2006).
34. Moccetti, I. & Bachis, A. Brain-derived neurotrophic factor activation of TrkB protects neurons from HIV-1/gp120-induced cell death. Critical reviews in neurobiology 16, 51–57 (2004).
35. Friedman, W. J. Neurotrophins induce death of hippocampal neurons via the p75 receptor. J Neurosci 20, 6340–6346 (2000).
36. Panigrahy, D. et al. Epoxyeicosanoids promote organ and tissue regeneration. Proceedings of the National Academy of the United States of America 110, 13528–13533 (2013).
37. Wu, H. et al. Soluble epoxide hydrolyase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex. J Biomed Sci 22, 94 (2015).
38. Winder, D. G. et al. ERK plays a regulatory role in induction of LTP by theta frequency stimulation and its modulation by beta-adrenergic receptors. Neuron 24, 715–726 (1999).
39. Minichiello, L. TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 10, 850–860 (2009).
40. Caldeira, M. V. et al. Brain-derived neurotrophic factor regulates the expression and synaptic delivery of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits in hippocampal neurons. J Biol Chem 282, 12619–12628 (2007).
41. Minichiello, L. et al. Essential Role for TrkB Receptors in Hippocampus-Mediated Learning. Neuron 24, 401–416 (1999).
42. Zorner, B. et al. Forebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than "depressive". Biol Psychiatry 54, 972–982 (2003).
43. Harada, C. et al. Glia- and neuron-specific functions of TrkB signalling during retinal degeneration and regeneration. 2, 189 (2011).
44. Villasana, L. E., Klann, E. & Tejada-Simon, M. V. Rapid isolation of synaptoneuroses and postsynaptic densities from adult mouse hippocampus. J Neurosci Methods 158, 30–36 (2006).
45. Schmidt-Kastner, R. et al. Transient changes of brain-derived neurotrophic factor (BDNF) mRNA expression in hippocampus during moderate ischemia induced by chronic bilateral common carotid artery occlusions in the rat. Brain research. Molecular brain research 92, 157–166 (2001).
46. Koerner, I. P. et al. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J Neurosci 27, 4642–4649 (2007).
47. Kuraoka, M. et al. Direct Experimental Occlusion of the Distal Middle Cerebral Artery Induces High Reproductibility of Brain Ischemia in Mice. Experimental Animals 58, 19–29 (2009).
48. Morisseau, C. et al. Structural refinement of inhibitors of uraese-based soluble epoxide hydrolases. Biochemical pharmacology 63, 1599–1608 (2002).
49. Hamm, R. J., Pike, B. R., O’Dell, D. M., Lyeth, B. G. & Jenkins, L. W. The rotorod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 11, 187–196 (1994).
50. Bouet, V. et al. Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse. Exp Neurool 203, 555–567 (2007).
51. Tennant, K. A. & Jones, T. A. Sensorimotor behavioral effects of endothelin-1 induced small cortical infarcts in C57BL/6 mice. J Neurosci Methods 181, 18–26 (2009).
52. Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L. & Bland, S. T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39, 777–787 (2000).
53. Huang, S.-S. et al. Anti-oxidative, anti-apoptotic, and pro-angiogenic effects mediate functional improvement by sonic hedgehog against focal cerebral ischemia in rats. Experimental Neurology 247, 680–688 (2013).
54. Gill, S. S., Ota, K. & Hammock, B. D. Radiometric assays for mammalian epoxide hydrolases and glutathione S-transferase. Analytical biochemistry 131, 273–282 (1983).
55. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Meth 9, 671–675 (2012).
56. Lin, H.-C., Mao, S.-C. & Gean, P.-W. Block of gamma-Aminobutyric Acid-A Receptor Insertion in the Amygdala Impairs Extinction of Conditioned Fear. Biological Psychiatry 66, 665–673 (2009).
57. Dias, R. R., Rombo, D. M., Ribeiro, J. A. & Sebastiao, A. M. Ischemia-induced synaptic plasticity drives sustained expression of calcium-permeable AMPA receptors in the hippocampus. Neuropharmacology 65, 114–122 (2013).
58. Taylor, C. P., Weber, M. L., Gaughan, C. L., Lehning, E. J. & LoPachin, R. M. Oxygen/glucose deprivation in hippocampal slices: altered intraneuronal elemental composition predicts structural and functional damage. J Neurosci 19, 619–629 (1999).

Acknowledgements
We thank Pei-Chien Hsu, Yu-Ling Gan and Dr. Pei-Chien Tsai for skilled technical support. This work was supported by the Taiwan Ministry of Science and Technology (MOST, 104–2320-B-075-001, 105–2320-B-075-001, 106–2314–B–075–019–MY3), the Taipei Veterans General Hospital (V105C-059, V106C-023) and National...
Yang-Ming University (Brain Research Center, Aim for the Top University Plan). We also thank the Clinical Research Core Laboratory of the Taipei Veterans General Hospital for providing experimental space and facilities. The authors have no disclosures to declare.

**Author Contributions**
Study concept and design: S.S.H., H.C.L., Y.Y.C., Y.H.L., I.H.L. Data acquisition and analysis: L.H.C., I.C.C., S.S.H., K.W.C., C.L.C. and Y.W.L. Drafting the manuscript and figures: L.H.C., I.C.C., K.W.C., Y.C.L., Y.H.L. and I.H.L. All authors edited and approved the final version of the manuscript.

**Additional Information**
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-18558-6.

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017